We lead next-generation drug delivery platforms based on advanced technologies and devices.
Intranasal
Drug Delivery Platform
The intranasal delivery platform administers drugs directly into the nasal cavity, overcoming the limitations of conventional administration routes and presenting a new therapeutic approach.
01
Patient-Friendly and Non-Invasive Administration
02
Reduced Drug Loss via Avoidance of Hepatic First-Pass Metabolism
03
Rapid Onset and Ease of Use
04
Direct Nose-to-Brain Delivery (Olfactory Pathway)
Focus areas
Neuropsychiatric Disorders
Application to psychiatric and cognitive disorders via the olfactory nerve and lymphatic system
Depression
Dementia
Alzheimer’s disease
Respiratory Infectious Diseases
Prevention and treatment of respiratory diseases through intranasal barrier formation and drug administration
Viral infections
Respiratory diseases
Metabolic Disorders
Improvement of the low bioavailability (BA) of signaling molecules via the intranasal route of administration.
Obesity
Growth hormone
Neuropsychiatric Disorders
Application to psychiatric and cognitive disorders via the olfactory nerve and lymphatic system
Depression
Dementia
Alzheimer’s disease
Respiratory Infectious Diseases
Prevention and treatment of respiratory diseases through intranasal barrier formation and drug administration
Viral infections
Respiratory diseases
Metabolic Disorders
Improvement of the low bioavailability (BA) of signaling molecules via the intranasal route of administration.
Obesity
Growth hormone
Core Competency
Defining new paradigms in treatment through advanced technology and differentiated research
Core Competency 01
Optimized Intranasal Formulation Design
The core of the intranasal spray platform lies in precise drug targeting and retention within the nasal cavity.
Daewoong Pharmaceutical maximizes delivery efficiency through formulation design optimized for intranasal administration, supported by precise control of spray angle, viscosity, and residence time.
01
Intranasal-Optimized Formulation Design
All intranasal spray products undergo a precise formulation process that considers spray angle, spray coverage area, and particle size distribution. This enables optimized drug delivery efficiency and retention within the nasal cavity.
Optimization of spray area and spray angle through viscosity-dependent evaluation
Daewoong has established a specialized nasal device evaluation infrastructure capable of conducting tests in accordance with U.S. FDA nasal spray guidelines. It is the only facility of its kind in Korea. Through this infrastructure, formulation performance during intranasal administration is precisely evaluated, and spray behavior within the nasal cavity is quantitatively modeled through controlled variable setting.
Evaluation of spray pattern and plume geometry
Measurement of droplet size distribution using Spraytec
Assessment of drug deposition and safety using NGI
Verification of spray weight/content uniformity using SWC
02
Tailored Absorption Time Based on Intended Use
The nasal cavity is a narrow and specialized route of administration, requiring formulations that overcome physiological barriers while maintaining sufficient residence time for optimal absorption. Based on its patented technology*, Daewoong Pharmaceutical enables precise control of intranasal adhesion and residence time, allowing optimization of absorption profiles according to therapeutic purpose.
* (Patent No. KR 10-2705817)
In Vivo Evaluation of Formulation Retention in the Nasal Cavity
Osmometer
Viscometer
03
Enhanced Drug Delivery through Optimized Intranasal Deposition
Effective intranasal drug delivery depends on accurate deposition at the target site. Daewoong utilizes proprietary nasal cavity models based on scientific evidence to analyze formulation distribution. This enables uniform and wide deposition, improving delivery efficiency and therapeutic outcomes.
Up to a 10.3‑fold increase in deposition area through formulation design
In Daewoong’s proprietary nasal cavity model, the intranasal formulation shows uniform distribution
extending to the upper nasal cavity compared with competitor formulations
Core Competency 02
Device Development and Spray Pattern Evaluation
The performance of a finished formulation is directly linked to the performance of the intranasal delivery device. Daewoong Pharmaceutical possesses a broad range of device technologies not limited by actuation frequency, patient age, or formulation type, enabling customized design aligned with intended applications.
01
Nasal Device Development Integrating Age, Formulation, and Delivery Mode
Intranasal administration requires specific spray conditions depending on patient population, dosing regimen, and safety considerations. Daewoong develops and handles a full range of nasal delivery devices—from single-dose to multi-dose—tailored to the intended use. Through collaboration with global pharmaceutical companies, Daewoong has established capabilities covering key quality attributes.
Design and development of human-use devices meeting requirements for nose-to-brain drug delivery based on integrated criteria including patient age, formulation, and spray mechanism
In-house development of animal intranasal dosing devices reflecting anatomical differences for nonclinical evaluation
Core Competency 03
Nasal-Specialized GMP Manufacturing Facility
Daewoong Pharmaceutical has established a dedicated GMP manufacturing site for intranasal products at its Hyangnam plant,
enabling CDMO and CMO collaboration.
Filling systems for single-dose and bi-dose nasal devices
Filling systems for multi-dose nasal devices
Product Portfolio
Medical DeviceNoseGuard Spray
Forms a physical barrier on the nasal mucosa after intranasal administration for the purpose of protecting the nasal mucosa
OTCCO-MEKINA Spray
Relief of nasal congestion, rhinorrhea, sneezing, and head heaviness associated with common cold (acute rhinitis), allergic rhinitis, or sinusitis
OTCNasomega Nasal Spray(140dose)
Treatment of seasonal allergic rhinitis, perennial rhinitis, and nasal polyps